$BCDA
BioCardia, Inc.

2018 Q1 Form 10-Q Financial Statement

#000143774918009379 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $199.0K $137.0K
YoY Change 45.26% -23.03%
Cost Of Revenue $157.0K $175.0K
YoY Change -10.29% -22.57%
Gross Profit $42.00K -$38.00K
YoY Change -210.53% -20.83%
Gross Profit Margin 21.11% -27.74%
Selling, General & Admin $1.707M $1.804M
YoY Change -5.38% 207.33%
% of Gross Profit 4064.29%
Research & Development $1.955M $1.033M
YoY Change 89.25% 134.24%
% of Gross Profit 4654.76%
Depreciation & Amortization $22.00K $13.00K
YoY Change 69.23% 30.0%
% of Gross Profit 52.38%
Operating Expenses $3.662M $2.837M
YoY Change 29.08% 175.97%
Operating Profit -$3.620M -$2.875M
YoY Change 25.91% 167.19%
Interest Expense $40.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $36.00K -$1.000K
YoY Change -3700.0% -99.76%
Pretax Income -$3.580M -$2.880M
YoY Change 24.31% -3700.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.584M -$2.876M
YoY Change 24.62% 92.25%
Net Earnings / Revenue -1801.01% -2099.27%
Basic Earnings Per Share
Diluted Earnings Per Share -$842.4K -$679.2K
COMMON SHARES
Basic Shares Outstanding 457.7M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.650M $19.03M
YoY Change -49.29% 36.61%
Cash & Equivalents $9.653M $19.03M
Short-Term Investments
Other Short-Term Assets $280.0K $250.0K
YoY Change 12.0% 1150.0%
Inventory $148.0K $144.0K
Prepaid Expenses $277.0K $252.0K
Receivables $127.0K $121.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.21M $19.55M
YoY Change -47.8% 40.14%
LONG-TERM ASSETS
Property, Plant & Equipment $152.0K $177.0K
YoY Change -14.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $54.00K $54.00K
YoY Change 0.0%
Total Long-Term Assets $206.0K $231.0K
YoY Change -10.82%
TOTAL ASSETS
Total Short-Term Assets $10.21M $19.55M
Total Long-Term Assets $206.0K $231.0K
Total Assets $10.41M $19.78M
YoY Change -47.37% 41.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $738.0K $291.0K
YoY Change 153.61%
Accrued Expenses $579.0K $720.0K
YoY Change -19.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.121M $1.368M
YoY Change 55.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $80.00K $60.00K
YoY Change 33.33%
Total Long-Term Liabilities $80.00K $60.00K
YoY Change 33.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.121M $1.368M
Total Long-Term Liabilities $80.00K $60.00K
Total Liabilities $2.204M $1.430M
YoY Change 54.13%
SHAREHOLDERS EQUITY
Retained Earnings -$75.99M -$63.02M
YoY Change 20.58%
Common Stock $38.00K $458.0K
YoY Change -91.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.207M $18.35M
YoY Change
Total Liabilities & Shareholders Equity $10.41M $19.78M
YoY Change -47.37% 41.79%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$3.584M -$2.876M
YoY Change 24.62% 92.25%
Depreciation, Depletion And Amortization $22.00K $13.00K
YoY Change 69.23% 30.0%
Cash From Operating Activities -$3.036M -$2.278M
YoY Change 33.27% 203.73%
INVESTING ACTIVITIES
Capital Expenditures $5.000K $64.00K
YoY Change -92.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$5.000K -$64.00K
YoY Change -92.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000K 22.00K
YoY Change -77.27%
NET CHANGE
Cash From Operating Activities -3.036M -2.278M
Cash From Investing Activities -5.000K -64.00K
Cash From Financing Activities 5.000K 22.00K
Net Change In Cash -3.036M -2.320M
YoY Change 30.86% 209.33%
FREE CASH FLOW
Cash From Operating Activities -$3.036M -$2.278M
Capital Expenditures $5.000K $64.00K
Free Cash Flow -$3.041M -$2.342M
YoY Change 29.85% 212.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1323000
CY2017Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1263000
CY2018Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5696406
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3878260
CY2018Q1 us-gaap Assets
Assets
10411000
CY2017Q4 us-gaap Assets
Assets
13538000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
10205000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
13315000
CY2018Q1 bcda Grant Liability Current
GrantLiabilityCurrent
654000
CY2017Q4 bcda Grant Liability Current
GrantLiabilityCurrent
663000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
738000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
902000
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
127000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
95000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
579000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
539000
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
779000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
758000
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84157000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83537000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
615000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
622000
CY2017Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
175000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
3819000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38241244
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38218660
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38241244
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38218660
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
38000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9653000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12689000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21352000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19032000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3036000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2320000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
157000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
3012000
CY2018Q1 us-gaap Customer Deposits Current
CustomerDepositsCurrent
90000
CY2017Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
61000
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
83000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
81000
CY2018Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
60000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
167000
CY2018Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2018Q1 us-gaap Depreciation
Depreciation
22000
CY2017Q1 us-gaap Depreciation
Depreciation
13000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6700000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-164000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-249000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
47000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
34000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
157000
CY2018Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
2000
CY2017Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
6000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-35000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1000
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-43000
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-63000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-104000
CY2018Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
55000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
29000
CY2018Q1 us-gaap Inventory Net
InventoryNet
148000
CY2017Q4 us-gaap Inventory Net
InventoryNet
191000
CY2018Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
78000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
70000
CY2018Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
15000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
92000
CY2018Q1 us-gaap Inventory Write Down
InventoryWriteDown
2000
CY2017Q1 us-gaap Inventory Write Down
InventoryWriteDown
9000
CY2018Q1 us-gaap Liabilities
Liabilities
2204000
CY2017Q4 us-gaap Liabilities
Liabilities
2413000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10411000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13538000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2121000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2332000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3036000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2278000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3584000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2876000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
36000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3620000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2875000
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2018Q1 us-gaap Other Operating Income
OtherOperatingIncome
36000
CY2017Q1 us-gaap Other Operating Income
OtherOperatingIncome
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
277000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
340000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22000
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
931000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
927000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
152000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1955000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1033000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75988000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72450000
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
199000
CY2017Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
137000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1707000
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1804000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
615000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
622000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20833
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1429075
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.86
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4213100
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5618854
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.96
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.85
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.80
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.56
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.60
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2488
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
8207000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
11125000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align: middle; width: 5%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(c)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation.</div></div></div></div></div></div>
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38236056
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38137881

Files In Submission

Name View Source Status
0001437749-18-009379-index-headers.html Edgar Link pending
0001437749-18-009379-index.html Edgar Link pending
0001437749-18-009379.txt Edgar Link pending
0001437749-18-009379-xbrl.zip Edgar Link pending
bcda-20180331.xml Edgar Link completed
bcda-20180331.xsd Edgar Link pending
bcda-20180331_cal.xml Edgar Link unprocessable
bcda-20180331_def.xml Edgar Link unprocessable
bcda-20180331_lab.xml Edgar Link unprocessable
bcda-20180331_pre.xml Edgar Link unprocessable
bcda20180331_10q.htm Edgar Link pending
ex_112872.htm Edgar Link pending
ex_112873.htm Edgar Link pending
ex_112874.htm Edgar Link pending
ex_112875.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending